Holen Sie sich die Stockscreener-App
0.70
5.02%
-0.037
Handel nachbörslich:
.70
Schlusskurs vom Vortag:
$0.737
Offen:
$0.718
24-Stunden-Volumen:
294.00K
Relative Volume:
0.04
Marktkapitalisierung:
$16.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.28M
KGV:
-0.0503
EPS:
-13.91
Netto-Cashflow:
$-13.75M
1W Leistung:
-8.10%
1M Leistung:
-22.65%
6M Leistung:
+0.00%
1J Leistung:
-51.05%
1-Tages-Spanne:
$0.6819
$0.7403
1-Wochen-Bereich:
$0.6819
$0.7834
52-Wochen-Spanne:
$0.281
$3.79
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Firmenname
Pasithea Therapeutics Corp
Sektor
Branche
Telefon
(702) 514-4174
Adresse
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.70 | 17.02M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten
Aug PreEarnings: Why Pasithea Therapeutics Corp. Equity Warrant stock could be next big winnerTrade Analysis Summary & AI Enhanced Trade Execution Alerts - mfd.ru
Earnings Miss: Is Pasithea Therapeutics Corp Equity Warrant stock overvalued or fairly pricedJuly 2025 Trends & Capital Efficiency Focused Strategies - baoquankhu1.vn
Dividend Watch: What is the Moat Score of Pasithea Therapeutics Corp Equity WarrantGDP Growth & Stock Market Timing Techniques - baoquankhu1.vn
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aug Levels: Can Pasithea Therapeutics Corp disrupt its industryWeekly Loss Report & Weekly High Momentum Picks - baoquankhu1.vn
Meme Stocks: Can Beyond Meat Inc. navigate macro headwindsRate Cut & Weekly Sector Rotation Insights - baoquankhu1.vn
Jobs Data: What is the long term forecast for Pasithea Therapeutics Corp stockJuly 2025 Fed Impact & Long-Term Safe Investment Plans - baoquankhu1.vn
Weekly Earnings: Can Pasithea Therapeutics Corp disrupt its industryQuarterly Trade Review & Growth-Oriented Investment Plans - baoquankhu1.vn
Institution Moves: Can Alerus Financial Corporation withstand a market correctionBond Market & Daily Entry Point Trade Alerts - baoquankhu1.vn
Is Pasithea Therapeutics Corp. stock influenced by commodity prices2025 Historical Comparison & Consistent Profit Trading Strategies - Mfd.ru
Pasithea Therapeutics Shareholders Approve Expanded Equity Authorization - TipRanks
Fundamentals Check: Is POET benefiting from innovation trends2025 Key Highlights & Accurate Intraday Trade Tips - baoquankhu1.vn
Performance Recap: Should I average down on WRAP stockMarket Movers & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Aug Shorts: Can Pasithea Therapeutics Corp sustain earnings growth2025 Bull vs Bear & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
How does SWVL compare to its peersEarnings Recap Summary & High Yield Stock Recommendations - baoquankhu1.vn
Published on: 2026-01-22 13:20:30 - baoquankhu1.vn
Aug Big Picture: Is Finward Bancorp benefiting from interest rate changes2025 Investor Takeaways & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Pasithea Therapeutics regains Nasdaq compliance - MSN
New Highs: Can Pasithea Therapeutics Corp grow without external fundingJuly 2025 Closing Moves & Breakout Confirmation Trade Signals - baoquankhu1.vn
Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway - TipRanks
Pasithea provides updates on clinical trials for MEK inhibitor drug By Investing.com - Investing.com Canada
Pasithea provides updates on clinical trials for MEK inhibitor drug - Investing.com
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines - Investing News Network
Pasithea Therapeutics Updates Clinical Trial Timelines for PAS-004 in Neurofibromatosis and Advanced Cancer - Quiver Quantitative
Risk Hedge: Is Pasithea Therapeutics Corp Equity Warrant impacted by rising ratesMarket Growth Summary & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Pasithea Therapeutics (NASDAQ:KTTA) Stock Rating Upgraded by Wall Street Zen - Defense World
How Pasithea Therapeutics Corp. Equity Warrant stock reacts to oil pricesJuly 2025 EndofMonth & Stepwise Trade Execution Plans - ulpravda.ru
How analysts rate Pasithea Therapeutics Corp. stock today2025 Trade Ideas & Weekly Chart Analysis and Trade Guides - ulpravda.ru
Why hedge funds are buying Pasithea Therapeutics Corp. stock2025 Momentum Check & Verified Swing Trading Watchlists - ulpravda.ru
What is the fair value of Pasithea Therapeutics Corp. Equity Warrant stock now2025 Bull vs Bear & Daily Growth Stock Tips - ulpravda.ru
Why Pasithea Therapeutics Corp. stock remains undervaluedJuly 2025 Selloffs & Daily Entry Point Trade Alerts - Улправда
How Pasithea Therapeutics Corp. stock benefits from strong dollar2025 Risk Factors & Short-Term High Return Ideas - Улправда
How Pasithea Therapeutics Corp. stock compares to industry benchmarks2025 Investor Takeaways & Free Expert Verified Stock Movement Alerts - ulpravda.ru
Why Did KTTA Stock Soar A Whopping 48% Today? - MSN
Is Pasithea Therapeutics Corp. Equity Warrant stock a dividend growth opportunity2026 world cup usa national team quarterfinals star players transition play group prediction analysis - ulpravda.ru
Will Pasithea Therapeutics Corp. Equity Warrant stock deliver shareholder value2026 world cup usa national team quarterfinals young talents transition play knockout prediction tactical review - ulpravda.ru
Pasithea Therapeutics Corp Stock Analysis and ForecastMomentum Trading Signals & Big Profit Low Capital - earlytimes.in
Is Pasithea Therapeutics Corp. overvalued or undervalued? - MarketsMojo
Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated - MSN
Can Pasithea Therapeutics Corp. stock hit analyst price targetsWeekly Stock Analysis & Safe Entry Momentum Stock Tips - Улправда
What sentiment indicators say about Pasithea Therapeutics Corp. Equity Warrant stockJuly 2025 Pullbacks & Reliable Entry Point Trade Alerts - Улправда
Is Pasithea Therapeutics Corp. Equity Warrant stock cheap at current valuationTrade Volume Summary & Weekly Sector Rotation Insights - Улправда
Will Pasithea Therapeutics Corp. stock return to pre crisis levelsWeekly Investment Report & Fast Gaining Stock Strategy Reports - Улправда
What hedge fund activity signals for Pasithea Therapeutics Corp. Equity Warrant stockLong Setup & Accurate Entry and Exit Point Alerts - Улправда
Finanzdaten der Pasithea Therapeutics Corp-Aktie (KTTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):